Heather J Cordell, James J Fryett, Kazuko Ueno, Rebecca Darlay, Yoshihiro Aiba, Yuki Hitomi, Minae Kawashima, Nao Nishida, Seik-Soon Khor, Olivier Gervais, Yosuke Kawai, Masao Nagasaki, Katsushi Tokunaga, Ruqi Tang, Yongyong Shi, Zhiqiang Li, Brian D Juran, Elizabeth J Atkinson, Alessio Gerussi, Marco Carbone, Rosanna Asselta, Angela Cheung, Mariza de Andrade, Aris Baras, Julie Horowitz, Manuel A R Ferreira, Dylan Sun, David E Jones, Steven Flack, Ann Spicer, Victoria L Mulcahy, Jinyoung Byan, Younghun Han, Richard N Sandford, Konstantinos N Lazaridis, Christopher I Amos, Gideon M Hirschfield, Michael F Seldin, Pietro Invernizzi, Katherine A Siminovitch, Xiong Ma, Minoru Nakamura, George F Mells
BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intrahepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening...
September 2021: Journal of Hepatology